AU5397300A - Pharmaceutical composition for intranasal use of active substances that are insoluble and/or hardly soluble in water - Google Patents

Pharmaceutical composition for intranasal use of active substances that are insoluble and/or hardly soluble in water

Info

Publication number
AU5397300A
AU5397300A AU53973/00A AU5397300A AU5397300A AU 5397300 A AU5397300 A AU 5397300A AU 53973/00 A AU53973/00 A AU 53973/00A AU 5397300 A AU5397300 A AU 5397300A AU 5397300 A AU5397300 A AU 5397300A
Authority
AU
Australia
Prior art keywords
insoluble
water
pharmaceutical composition
active substances
hardly soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU53973/00A
Inventor
Norbert Klocker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hexal AG
Original Assignee
Hexal AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999125290 external-priority patent/DE19925290A1/en
Priority claimed from DE1999136543 external-priority patent/DE19936543A1/en
Application filed by Hexal AG filed Critical Hexal AG
Publication of AU5397300A publication Critical patent/AU5397300A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
AU53973/00A 1999-06-02 2000-05-26 Pharmaceutical composition for intranasal use of active substances that are insoluble and/or hardly soluble in water Abandoned AU5397300A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE1999125290 DE19925290A1 (en) 1999-06-02 1999-06-02 Stable, well-tolerated composition for intranasal administration of water-insoluble drugs e.g. scopolamine, comprising solution of drug in neutral oil, especially triglyceride
DE19925290 1999-06-02
DE1999136543 DE19936543A1 (en) 1999-08-03 1999-08-03 Composition for intranasal administration of water-insoluble drugs, e.g. scopolamine, budesonide or diazepam, comprising a solution of the water-insoluble or sparingly water-soluble drug in a neutral oil e.g. a triglyceride
DE19936543 1999-08-03
PCT/EP2000/004799 WO2000074651A1 (en) 1999-06-02 2000-05-26 Pharmaceutical composition for intranasal use of active substances that are insoluble and/or hardly soluble in water

Publications (1)

Publication Number Publication Date
AU5397300A true AU5397300A (en) 2000-12-28

Family

ID=26053616

Family Applications (1)

Application Number Title Priority Date Filing Date
AU53973/00A Abandoned AU5397300A (en) 1999-06-02 2000-05-26 Pharmaceutical composition for intranasal use of active substances that are insoluble and/or hardly soluble in water

Country Status (4)

Country Link
EP (1) EP1185246A1 (en)
JP (1) JP2004525854A (en)
AU (1) AU5397300A (en)
WO (1) WO2000074651A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044356A1 (en) * 2001-04-20 2003-03-06 Jin Auh Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one)
DE10136228A1 (en) * 2001-07-25 2003-03-06 Wolfgang KOX Receptor-adapted nicotine supply through anticholinergic and noradrenergic blockade
AU2004212976A1 (en) * 2003-02-19 2004-09-02 Biovail Laboratories Inc. Rapid absorption selective 5-HT agonist formulations
ITMI20032054A1 (en) 2003-10-22 2005-04-23 Monteres S R L PROCESS FOR THE PREPARATION OF PHARMACEUTICAL SUSPENSIONS TO BE INHALED.
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
US20070202050A1 (en) * 2006-02-09 2007-08-30 Julianne Berry Pharmaceutical Formulations
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
DE202010012096U1 (en) * 2010-09-02 2010-11-11 Lorentz, Eckart, Dr. med. nose drops
CN109758435A (en) * 2017-11-09 2019-05-17 郑州泰丰制药有限公司 Omeprazole aerosol and preparation method thereof
WO2024026463A1 (en) * 2022-07-28 2024-02-01 Happy Healing Inc. Composition for nasal delivery of an active compound

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7880991A (en) * 1990-05-10 1991-11-27 Novo Nordisk A/S A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols
DE69208660T2 (en) * 1991-06-10 1996-07-11 Schering Corp FLUORINE CHLORINE HYDROGEN-FREE AEROSOL FORMULATIONS
BR9711843A (en) * 1996-10-01 2001-07-31 Smithkline Beecham Corp Use of mupirocin for the manufacture of a medicine for the treatment of bacterial infections associated with colonization of the nasopharynx by pathogenic organisms

Also Published As

Publication number Publication date
WO2000074651A1 (en) 2000-12-14
EP1185246A1 (en) 2002-03-13
JP2004525854A (en) 2004-08-26

Similar Documents

Publication Publication Date Title
AU6404100A (en) Water soluble polymer composition and method of use
HUP0200548A2 (en) Pharmaceutical compositions and their use
HUP0103575A3 (en) Inhibitors of caspases, pharmaceutical compositions comprising thereof and their use
AU5440901A (en) Cosmetic and/or pharmaceutical preparations
IL144508A0 (en) Compositions and methods for use in targeting vascular destruction
HK1048247A1 (en) Stable carotene-xanthophyll beadlet compositions and methods of use
HUP0201214A3 (en) Inhibitors of impdh enzyme, pharmaceutical compositions containing them and their use
PL348193A1 (en) Self-emulsifying compositions for drugs poorly soluble in water
HUP0202501A3 (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors, pharmaceutical compositions containing them and their use
HUP0203588A3 (en) Analgesic pharmaceutical compositions and their use
HUP0203563A3 (en) Fungicidal combinations of active substances and use thereof
AU1939801A (en) In situ bioreactors and methods of use thereof
HUP0300318A3 (en) Pyrazolobenzodiazepines as cdk2 inhibitors and pharmaceutical compositions containing them and their use
AUPQ010299A0 (en) Improvements in or relating to trading and settlement
HUP0203575A3 (en) Pharmaceutical compositions containing th2 differentiation inhibitors and their use
AU4303600A (en) Pharmaceutical composition in unit form containing acetylsalcylic acid and clopidogrel hydrogenosulphate
AU4340700A (en) Methods and compositions for use in the treatment of hyperlipidemia
AU3240000A (en) Hydrophobic and particulate soil removal composition
AU2300001A (en) Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
AU5397300A (en) Pharmaceutical composition for intranasal use of active substances that are insoluble and/or hardly soluble in water
AP2001002371A0 (en) Streptogramin derivatives preparation and compositions containing them
AU7651100A (en) Pharmaceutical and/or cosmetical compositions
HUP0200468A3 (en) Resorcinol derivatives and pharmaceutical compositions containing them
AU2438400A (en) Cosmetic and/or pharmaceutical preparations
AU4293800A (en) Cosmetic and/or pharmaceutical preparations

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase